GENE ONLINE|News &
Opinion
Blog

2021-10-07| In-DepthSpecial

Expanding Deals and Investments Underscore Burgeoning Market of Targeted Protein Degradation

by Rajaneesh K. Gopinath
Share To
As opposed to large molecule biologics such as monoclonal antibodies, vaccines, or other proteins, small molecule drugs offer several advantages. Their small size, low immunogenicity, easy permeability, and most importantly, a simple and stable structure allow them to hit a therapeutic target better. Also, they are easily convertible to the oral form, and they are very cost-effective.

The biopharma industry spends millions on small molecule drug discovery, and forecasters estimate that the market will reach $50,823.06 million in value by 2027. However, the process of bringing small molecule drugs to the clinic is long, even though their manufacturing is relatively simple.

In addition to the technical challenges, often, only one out of every 10,000 compounds go on to obtain regulatory approval. Therefore, as opposed to the conventional drugs that block protein activity, the industry is now pursuing a new type of small molecule known as “Targeted protein degraders”. This exciting technology has become a hot commodity for drug discovery, giving way to large deal-making between companies and the launch of new startups that are racking in the big bucks.

GO Prime with only $1.49 now

LATEST
Axsome’s AXS-05 Achieves Endpoints In Alzheimer’s Agitation Trial
2022-11-29
Spectrum to Cut 75% of Staff and NSCLC Program Following CLR
2022-11-28
Full-Life Technologies to Acquire Focus-X Therapeutics, Bolstering Peptide-Focused Radiopharmaceutical Pipeline
2022-11-28
Medeologix Acquires Three Silicon Valley Medical Device CDMO Companies and Establishes One-Stop Shop Mass Production Facilities in Taiwan
2022-11-28
GenFleet Therapeutics to Present Data from Phase I Trial of GFH009 Monotherapy at the 2022 Annual Meeting of American Society of Hematology (ASH)
2022-11-28
Everest’s Renal Drug Gets Placed On Fast Track For Approval In Taiwan And Korea
2022-11-28
Canada Authorizes Roche’s Polivy as First-Line Lymphoma Treatment
2022-11-27
EVENT
2022-12-01
BIOCHINA 2022
Online
2022-12-10
64TH ASH ANNUAL MEETING & EXPOSITION
New Orleans, USA
2022-12-14
BIOHK2022
Hong Kong, China
2023-01-07
7th Asia Microbiome Conference
Taipei, Taiwan
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!